The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. In December 2023, the Company ...
Medmira (TSE:MIR) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street analysts, ...
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ...
The Company's completed clinical trials showed a sensitivity of 100% for HIV-1 and HIV-2 MedMira's Reveal® G4 HIV-1/2 rapid antibody test achieved a flawless 100% specificity and was reactive in ...
Health Canada approves MedMira’s Multiplo Rapid TP/HIV test for Syphilis and HIV: Halifax, Canada Friday, December 27, 2024, 10:00 Hrs [IST] MedMira Inc. (MedMira), a leading de ...